Abatacept and rituximab increase cancer risk in patients with RA

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2036卷 / 1期
关键词：
D O I：
10.1007/s40278-024-71232-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [1] Cyclosporin does not increase cancer risk in patients with RA
    Reactions Weekly, 1999, 761 (1) : 5 - 5
  • [2] OVERALL CANCER RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS, TOCILIZUMAB, ABATACEPT, OR RITUXIMAB
    Wadstrom, H.
    Frisell, T.
    Askling, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 93 - 93
  • [3] In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo
    Pisetsky, David S.
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (07) : JC79 - JC79
  • [4] Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
    Gottenberg, Jacques-Eric
    Ravaud, Philippe
    Bardin, Thomas
    Cantagrel, Alain
    Combe, Bernard
    Dougados, Maxime
    Flipo, Rene Marc
    Vittecoq, Olivier
    Schaeverbeke, Thierry
    Pane, Isabelle
    Sibilia, Jean
    Mariette, Xavier
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study
    Westermann, Rasmus
    Cordtz, Rene Lindholm
    Duch, Kirsten
    Mellemkjaer, Lene
    Hetland, Merete Lund
    Magnussen, Bergur
    Dreyer, Lene
    RHEUMATOLOGY, 2024,
  • [6] Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards
    Strangfeld, Anja
    Richter, Adrian
    Herzer, Peter
    Rockwitz, Karin
    Demary, Winfried
    Aringer, Martin
    Zink, Angela
    Listing, Joachim
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease
    Chen, Ming-Han
    Lee, I-Cheng
    Chen, Ming-Huang
    Hou, Ming-Chih
    Tsai, Chang-Youh
    Huang, Yi-Hsiang
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (11) : 1393 - 1399
  • [8] Tumor necrosis factor antagonists do not increase cancer risk in patients with RA
    Rachel Murphy
    Nature Clinical Practice Rheumatology, 2006, 2 (1): : 5 - 6
  • [9] Rituximab, abatacept and anakinra do not increase the risk of serious infections: A metaanalysis of published randomised controlled trials
    Salliot, C.
    Gossec, L.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 436 - 437
  • [10] INCIDENCE OF CANCERS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND A HISTORY OF CANCER TREATED WITH RITUXIMAB OR ABATACEPT
    Gottenberg, J. E.
    Morel, J.
    Ravaud, P.
    Bardin, T.
    Cacoub, P.
    Cantagrel, A.
    Combe, B.
    Constantin, A.
    Dougados, M.
    Flipo, R. M.
    Godeau, B.
    Hachulla, E.
    Le Loet, X.
    Schaeverbeke, T.
    Sibilia, J.
    Pane, I.
    Baron, G.
    Mariette, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 478 - 479
12345